Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Benzinga Newsdesk www.benzinga.com Positive 55.6%

Neg 0% Neu 0% Pos 55.6%

Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.